

## Vidarabine Phosphate

[View the current Vidarabine Phosphate InDepth page on BioPortfolio.com \(PDF\)](#)

([http://www.bioportfolio.com/indepth/Vidarabine\\_Phosphate.html](http://www.bioportfolio.com/indepth/Vidarabine_Phosphate.html)) - Regularly Updated.

### Recent Publications on Vidarabine Phosphate:



- [Genzyme takes Campath bet.](#)  
*PURPOSE: The phase II CLL2H trial evaluated safety and efficacy of...*30th September, 2009  
- Nat Biotechnol. 2009 Jun;27(6):498. ([DOI Direct Link](#))
- [Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs.](#)  
*Nucleoside analogs are rationally designed anticancer agents that disrupt...*4th August, 2009  
Genzyme Corporation, Framingham,- Int J Oncol. 2009 May;34(5):1329-40.
- [Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.](#)  
*The purpose of this study was to determine the effect of alemtuzumab on...*18th June, 2009  
Section of Hematology/Oncology, University of Chicago, Chicago, Illinois- Biol Blood Marrow Transplant. 2009 May;15(5):610-7. ([DOI Direct Link](#))
- [Collision induced dissociation studies of alkali metal adducts of tetracyclines and antiviral agents by electrospray ionization, hydrogen/deuterium exchange and multiple stage mass spectrometry.](#)  
*The collision induced dissociation (CID) mass spectra were obtained for...*17th December, 2008  
Department of Exploratory Medicinal Sciences, Pfizer Global Research and- Eur J Mass Spectrom (Chichester, Eng). 2008;14(5):281-97. ([DOI Direct Link](#))
- [High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia.](#)  
*A multicentre single-arm study testing the efficacy and toxicity of the...*17th December, 2008  
Department of Haematology, Claude Huriez University Hospital, Lille,- Br J Haematol. 2008 Sep;143(1):54-9. Epub 2008 Aug 15. ([DOI Direct Link](#))
- [The combined effect of fludarabine monophosphate and radiation as well as gemcitabine and radiation on squamous carcinoma tumor cell lines in vitro.](#)  
*PURPOSE: Despite proven antitumor activity of gemcitabine in...*10th September, 2008  
Department of Radiation Oncology, Georg-August-Universitat Gottingen,- Int J Radiat Biol. 2008 Aug;84(8):643-57. ([DOI Direct Link](#))
- [F-ara-AMP is a substrate of cytoplasmic 5'-nucleotidase II \(cN-II\): HPLC and NMR studies of enzymatic dephosphorylation.](#)  
*Intracellular accumulation of triphosphorylated derivatives is essential...*2nd February, 2008  
INSERM U590, Laboratoire de Cytologie Analytique, Faculte de Medecine- Nucleosides Nucleotides Nucleic Acids. 2006 Mar;25(3):289-97.
- [Multifocal extranodal mucosa-associated lymphoid tissue lymphoma affecting the larynx.](#)  
*OBJECTIVES: Extranodal marginal B-cell lymphoma of mucosa-associated...*26th May, 2007

Department of Otorhinolaryngology-Head and Neck Surgery, University- Ann Otol Rhinol Laryngol. 2007 Apr;116(4):257-61.

- [Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts.](#)  
*We have developed unique replication-competent retroviral (RCR) vectors...*23rd March, 2007  
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York,- Cancer Gene Ther. 2007 Mar;14(3):279-86. Epub 2007 Jan 12. ([DOI Direct Link](#))
- [Simultaneous sustained release of fludarabine monophosphate and Gd-DTPA from an interstitial liposome depot in rats: potential for indirect monitoring of drug release by magnetic resonance imaging.](#)  
*INTRODUCTION: Cytostatic depot preparations are interstitially...*17th October, 2006  
Unit Pharmacology of Cancer Treatment, Department of Medical Physics in- Cancer Chemother Pharmacol. 2006 Nov;58(5):607-17. Epub 2006 Feb 28. ([DOI Direct Link](#))
- [Subcutaneous Taenia crassiceps infection in a patient with non-Hodgkin's lymphoma.](#)  
*Infections with larvae of Taenia crassiceps are rare in humans and have...*19th August, 2006  
Medical and Surgery Department, General Hospital Trostberg, Trostberg,- Am J Trop Med Hyg. 2006 Jul;75(1):108-11.
- [High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia.](#)  
*We report a high incidence of myelodysplastic syndrome (MDS)/acute myeloid...*4th May, 2006  
Department of Haematology, Birmingham Heartlands Hospital, Birmingham B9- Br J Haematol. 2006 Apr;133(2):173-5. ([DOI Direct Link](#))
- [Contrast-enhanced MR imaging in the indirect monitoring of drug release from an interstitial depot.](#)  
*Reduced intensity conditioning (RIC) for allogeneic stem cell...*4th May, 2006  
Unit Pharmacology of Cancer Treatment, German Cancer Research Center,- Int J Clin Pharmacol Ther. 2005 Dec;43(12):605-6.
- [Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma.](#)  
*PURPOSE: To compare the efficacy and safety of fludarabine phosphate with...*14th April, 2006  
European Organisation for Research and Treatment of Cancer (EORTC)- J Clin Oncol. 2006 Apr 1;24(10):1590-6. ([DOI Direct Link](#))
- [Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect.](#)  
*Reduced intensity conditioning (RIC) for allogeneic stem cell...*4th April, 2006  
Department of Haematology, University Hospital Aintree, Liverpool, UK.- Bone Marrow Transplant. 2006 Mar;37(5):455-61. ([DOI Direct Link](#))

## BioNews Results for Vidarabine Phosphate

- [Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder](#)  
*Bionity.com: Nov 21 2009 5:27AM Matching: phosphate*
- [Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder](#)  
*PharmaceuticalProcessing: Nov 20 2009 8:23PM Matching: phosphate*
- [Genzyme Announces Results Of Phase 2/3 Trial Of Advanced Phosphate Binder](#)  
*Medical News Today: Nov 20 2009 4:43PM Matching: phosphate*
- [Medical News: Genzyme Announces Results Of Phase 2/3 Trial Of Advanced Phosphate Binder](#)  
*BioFind: Nov 20 2009 12:57PM Matching: phosphate*
- [Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder](#)

- MDLinx: Nov 19 2009 11:21AM Matching: phosphate
- [Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder](#)  
SmartBrief: Nov 19 2009 2:58AM Matching: phosphate
  - [Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder](#)  
Biotech Intelligence: Nov 19 2009 2:01AM Matching: phosphate
  - [Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder](#)  
PharmiWeb: Nov 19 2009 1:43AM Matching: phosphate
  - [Genzyme Cancels Phosphate Binder Development](#)  
Contract Pharma: Nov 19 2009 1:24AM Matching: phosphate
  - [Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder](#)  
Individual.com: Nov 18 2009 9:25PM Matching: phosphate
  - [Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder](#)  
Pharma Live: Nov 18 2009 7:43PM Matching: phosphate
  - [Genzyme Stops Development Of Advanced Phosphate Binder - Update](#)  
RTTNews.com: Nov 18 2009 2:29PM Matching: phosphate
  - [Genzyme Corp. \(GENZ\) Announces Reports on Phase 2/3 for Advanced Phosphate Binder](#)  
Street Insider: Nov 18 2009 12:37PM Matching: phosphate
  - [Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder](#)  
Business Wire via Yahoo!: Nov 18 2009 12:36PM Matching: phosphate
  - [Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder](#)  
Genetic Engineering News: Nov 18 2009 12:30PM Matching: phosphate

## Vidarabine Phosphate Patents:



- 7615539- [Nucleic acid-lipophilic conjugates](#)
- 7153510- [Recombinant vesiculoviruses and their uses](#)
- 7101573- [Simethicone solid oral dosage form](#)
- 6890743- [Geminin and Orc3N inhibit replication of herpesviruses, papillomaviruses, and polyomaviruses](#)
- 6682761- [Water-insoluble drug particle process](#)
- 6634576- [Milled particles](#)
- 6604698- [Media milling](#)
- 6602902- [Dha-pharmaceutical agent conjugates to improve tissue selectivity](#)
- 6576636- [Method of treating a liver disorder with fatty acid-antiviral agent conjugates](#)
- 6495129- [Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 \(MPIF-1\) \(Ckbeta-8/MIP-3\)](#)
- 6245813- [Use of ubenimex and the pharmaceutical composition containing it for treating virus hepatitis](#)
- 6168943- [Methods for making modified recombinant vesiculoviruses](#)
- 5795909- [DHA-pharmaceutical agent conjugates of taxanes](#)
- 7199151- [DHA-pharmaceutical agent conjugates of taxanes](#)
- 7253159- [Methods and compositions for immunomodulation using CD1 antigens](#)
- 7605138- [Nucleic acid compositions for stimulating immune responses](#)
- 7601355- [Compositions and methods for altering immune function](#)
- 7576066- [Nucleic acid compositions for stimulating immune responses](#)

- 7569553- [Nucleic acid compositions for stimulating immune responses](#)
- 7566703- [Semi-soft C-class immunostimulatory oligonucleotides](#)
- 7563899- [\(S\)-N-methylalntrexone](#)
- 7491743- [Inhibitors of cellular necrosis](#)
- 7470428- [Compositions and methods related to TIM-3, a Th1-specific cell surface molecule](#)
- 7456220- [Immunodulatory compositions and methods of use thereof](#)
- 7351827- [Substituted oxetanes, method of making, and method of use thereof](#)
- 7351739- [Bioactive compounds and methods of uses thereof](#)
- 7271156- [Immunostimulatory nucleic acids](#)
- 5700666- [Process for the production of arabinonucleotides](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

